soul trial oral semaglutide cardiovascular outcomes nejm 2024 2025 π§Ώ is the first oral GLP-1 RA proven to reduce MACE in high-risk T2DM patients, extending protection beyond injectable formulations. Trial: Oral Semaglutide & Cardiovascular in T2DM soul trial oral semaglutide cardiovascular
Description
Effective for weight loss and type 2 diabetes
Lipo-C is a bottom-up approach
This robust design effectively protects your temperature-sensitive insulin, guarding them against heat damage during travel
Each capsule is enteric-coated to help safeguard probiotics as they pass through the stomach, ensuring optimal delivery to the GI tract
